Novo Nordisk Is Licensing a Chinese Weight-Loss Drug. Why the Stock Is Down.
Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...
Novo Signs $2 Billion Deal With United Labs for Obesity Drug
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
New Atlas5d
Next-gen weight-loss drugs will be here within 12 months
It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...
Victoria Advocate5d
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk Stock (NVO) Plunges as It Shells Out $2 Billion on Chinese Weight Drug
Novo Nordisk (NVO) just agreed to shell out up to $2 billion for the global rights to a Chinese weight-loss drug—and the market wasn’t ...
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
WFLA News Channel 83d
Novo Nordisk Raises Awareness of Chronic Kidney Disease & Type 2 Diabetes Treatment Option, Ozempic®
Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic®. If the label doesn’t say Ozempic® (semaglutide), it’s not FDA approved. Visit Ozempic.com to learn more ...
Medical Xpress5d
Novo Nordisk to pay $2 billion for new weight loss drug
Hong Kong, Macau and Taiwan. UBT251 is different from Novo Nordisk's current drugs like Ozempic and Wegovy. The drug combines GLP-1 and GIP, which lower appetite and blood sugar, with glucagon ...